GleamWall
中文EN

ZVRA ZEVRA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1434647 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY75.1%
TTM net income YoY120.8%
TTM EPS YoY159.6%
Revenue 3-yr CAGR106.2%
Net income 3-yr CAGR—

Margins

Gross margin95.4%
Operating margin60.8%
Net margin52.8%
FCF margin25.9%
EBITDA margin61.8%

Returns

ROE41.9%
ROA26.7%
ROIC (approx.)60.6%
Asset turnover0.51x

Leverage & solvency

Liabilities / assets23.8%
Debt / equity0.00x
Current ratio5.46x
Interest coverage24.55x

Cash quality & payout

Operating cash flow / net income0.50x
Accruals ratio13.5%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$106.47M$23.61M
Cost of revenue$16.48M$7.42M
Gross profit$89.99M$16.20M
R&D expense$12.74M$42.09M
SG&A expense$77.62M$54.87M
Operating income-$62.94M-$87.00M
Interest expense$7.98M$7.35M
Pretax income$86.68M-$90.14M
Income tax$3.45M$15.37M
Net income$83.23M-$105.51M
EBITDA-$58.89M-$80.61M
EPS (basic)1.40-2.28
EPS (diluted)1.35-2.28
Weighted avg. shares (diluted)57.26M46.25M
Balance sheet
Cash & equivalents$62.41M$33.78M
Short-term investments$128.60M$35.71M
Receivables—$10.18M
Inventory$1.74M$1.97M
Current assets$223.01M$86.03M
PP&E, net$489,000$356,000
Goodwill$4.70M$4.70M
Intangibles$6.42M$68.99M
Total assets$284.73M$178.13M
Current liabilities$39.28M$34.06M
Long-term debt$61.93M$59.50M
Total debt$61.93M$59.50M
Total liabilities$130.07M$138.46M
Shareholders' equity$154.66M$39.67M
Net debt-$478,000$25.72M
Shares outstanding56.85M53.67M
Cash flow statement
Operating cash flow-$1.60M-$69.67M
Capital expenditure$835,000$0
Free cash flow-$2.43M-$69.67M
Investing cash flow$18.13M-$22.16M
Financing cash flow$12.06M$82.11M
Depreciation & amortization$4.05M$6.39M
Stock-based compensation$12.63M$14.91M
Share buybacks—$0

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.